Dennis Novak
Pulmonary Disease · Newport Beach, CANPI 1336158211
Payments from drug & device makers
Across 342 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- AstraZeneca$1K
- GSK$915
- Mylan Specialty L.p.$748
- Grifols USA, LLC$600
- Takeda Pharmaceuticals U.S.A., Inc.$517
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,18899%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 49 | $1,700 |
| AstraZeneca | 64 | $1,223 |
| GSK | 46 | $915 |
| Mylan Specialty L.p. | 33 | $748 |
| Grifols USA, LLC | 23 | $600 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $517 |
| Regeneron Healthcare Solutions, Inc. | 12 | $414 |
| Philips North America LLC | 12 | $260 |
| Genentech USA, Inc. | 14 | $228 |
| Insmed, Inc. | 6 | $208 |
| Amgen | 6 | $181 |
| Sunovion Pharmaceuticals Inc. | 7 | $157 |
| Pfizer | 5 | $112 |
| Electromed, Inc. | 5 | $99 |
| Paratek Pharmaceuticals, Inc. | 4 | $93 |
| Advanced Respiratory, Inc | 4 | $91 |
| Baxter Healthcare | 3 | $89 |
| Covis Pharma GmbH | 2 | $66 |
| United Therapeutics Corporation | 3 | $64 |
| Johnson & Johnson | 3 | $61 |
| Merck | 3 | $53 |
| Octapharma USA, Inc. | 1 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Sanofi | 2 | $42 |
| Sanofi Pasteur Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| CSL Behring | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Pulmonx Corporation | 2 | $29 |
| Harmony Biosciences LLC | 1 | $29 |
| Shionogi Inc | 1 | $24 |
| Shire North American Group Inc | 1 | $23 |
| Endogastric Solutions, Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$112
How this compares
$8,288 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $35,803 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $30,815 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $18,940 |
| Spiriva RespimatTiotropium Bromide | 15 | $14,545 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,465 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,776 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $842 |
| Montelukast Sodium | 28 | $521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $915 | $85,558115 claims |
| Boehringer IngelheimSpiriva Respimat | $1,700 | $14,54515 claims |
| AstraZenecaSymbicort | $1,223 | $5,46520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Newport Beach
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.